Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for Maintenance of Clinical Remission in Japanese Subjects with Crohn's Disease
jRCT2080220358Phase 3
- Sponsor
- Abbott Laboratories
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Adalimumab with Placebo (2 arms).
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2080220358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220358.